Figure 2.

Stargazin lateral diffusion is increased during early stages of scaling down. (A) Scheme representing the experimental labeling strategy. Stargazin-HA (Stg-HA) particles were tracked using a primary antibody against the HA tag and Qdots-coupled to a secondary antibody. Representative trajectories of Stg-HA molecules (red—synaptic trajectories; blue—extrasynaptic trajectories), and Homer-GFP (white). Scale bar 2 μm. Cultured cortical neurons (DIV14) were transfected with stg-HA and Homer-GFP and treated with PTX at DIV16. (B) Mean square displacement (MSD) vs. time plot for DMSO and PTX treated neurons. Number of trajectories for DMSO 4 h = 1030 and for PTX 4 h = 520. (C) The median diffusion of stargazin was increased upon PTX treatment at extra-synaptic sites and (D) at synapses. Mann Whitney test, ****P < 0.0001. (E) PTX decreased the number of immobile extrasynaptic stargazin particles t-test, *P = 0.0347. Data was collected from ≥9 cells per condition, from two independent experiments.